Moderna’s MRNA-Based Flu Vaccine Shows Promise in Early-Stage Study

Published on December 10, 2021

Moderna Inc.’s messenger RNA-based experimental seasonal flu vaccine has produced robust antibodies against all four strains of the influenza virus in an early stage study, the vaccine maker said on Friday. The early-stage study is ongoing and a mid-stage study testing of…

Read Full Article (External Site)